JSPR
Jasper Therapeutics Inc
0.5652$
-5.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -14.1% | +32.7% | -9.6% | -12.7% | -19.6% | -27.9% | -19.3% | +23.7% | -37.7% | -40.8% | -44.3% | |
| – | -15.5% | +35.3% | -9.7% | -12.8% | -20.0% | -29.9% | -19.2% | +27.0% | -36.5% | -41.4% | -43.0% | |
| – | -16.3% | +36.4% | -9.8% | -13.4% | -22.6% | -31.9% | -19.0% | +28.8% | -43.6% | -50.7% | -48.3% | |
| – | -16.3% | +36.4% | -9.8% | -13.4% | -22.6% | -31.9% | -19.0% | +28.8% | -43.6% | -50.7% | -48.3% | |
| – | -6.7% | +0.0% | +0.0% | +0.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.1% | -22.6% | +7.0% | +15.5% | +15.8% | -15.8% | +49.6% | +99.9% | -31.1% | -43.8% | -41.6% | |
| – | +3.9% | -27.9% | +12.9% | +23.7% | +22.3% | -19.1% | +66.2% | +2.6% | -37.3% | -31.8% | -12.8% | |
| – | +2.9% | +2.9% | +2.9% | +2.9% | +2.8% | +68.5% | +6.5% | -12.8% | -27.5% | -38.7% | -64.3% | |
| – | +27.4% | -42.4% | +24.0% | +4.1% | +30.5% | -25.6% | +168.2% | +14.1% | -32.1% | -60.8% | +13.9% | |
| – | -16.7% | +44.4% | -11.4% | -16.6% | -26.3% | -31.5% | -44.4% | -50.8% | -64.1% | -18.1% | -58.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.7% | +20.7% | +12.4% | +0.1% | +0.1% | +0.1% | +2.1% | +8.5% | +72.3% | +0.0% | +0.1% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.